CRL · Earnings call · 2026Q2T · Full report
Capital Expenditures
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 31 · Surprise 40 · In source text
Second-quarter capital expenditures declined to $31 million, or approximately 3.1% of revenue, from $35 million in the prior-year quarter. Charles River is continuing a global laboratory-expansion program focused on bioanalytical capacity. The Scotland expansion at Heriot-Watt University’s Research Park is one of five ongoing lab-sciences expansions globally. Management said current DSA capacity is sufficient for near-term growth, but laboratory expansions will be needed over the next several years to support market growth.
Key facts
- Charles River embarked on an expansion to add bioanalytical laboratory capacity at Heriot-Watt University's Research Park in Scotland as one of five ongoing lab sciences expansions globally.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. is investing in lab space and lab expansions that won't impact 2026 revenue but will allow growth in 2027 and beyond.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. is planning a lab expansion in Edinburgh near a university to help with staffing.
- Capital expenditures declined to $31 million or approximately 3.1% of revenue in the second quarter from $35 million last year.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | committed | — | Charles River embarked on an expansion to add bioanalytical laboratory capacity at Heriot-Watt University's Research Park in Scotland as… |
| cash | negative | committed | — | Charles River embarked on an expansion to add bioanalytical laboratory capacity at Heriot-Watt University's Research Park in Scotland as… |